Kothari R, Doshi M, Chaithanya PK, Ct S, et al. A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta(R) in Patients With HER2-Positive Metastatic Breast Cancer. Clin Breast Cancer 2024 Jul 10:S1526-8209(24)00183.
PMID: 39069436